[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-multiple-myeloma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-multiple-myeloma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,42,65,86,108,130,153,176,196,217,235,255,275],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100533916","phase-1-testing-the-combination-of-two-approved-drugs-and-one-experimental-drug-in-patients-with-relapsed-or-refractory-multiple-myeloma-100533916",false,"NCT06232044","Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma","A Phase I\u002FII Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)\u002FDexamethasone Versus Belantamab Mafodotin (GSK2857916)\u002FDexamethasone in Relapsed Refractory Multiple Myeloma","* Documentation of disease: Diagnosis of multiple myeloma and have relapsed or refractory disease according to the IMWG criteria where:\n\n  * Progression of myeloma is defined by IMWG criteria as recurrence of disease after prior response, indicated as any of the following:\n\n    * ≥ 25% increase in M-protein (must be at least 0.5g\u002Fdl above nadir from last treatment regimen).\n    * 25% difference between involved and uninvolved serum free light chains from its nadir or\n    * The development of new plasmacytomas or hypercalcemia.\n  * Refractory myeloma as defined by IMWG criteria as disease which become non-responsive or progresses on therapy or within 60 days of last treatment in patients who had achieved a minimal response or better on prior therapy.\n* Measurable disease defined by IMWG criteria as:\n\n  * Serum M-protein ≥ 0.5 g\u002FdL.\n  * Urine monoclonal protein ≥ 200 mg\u002F24h.\n  * Serum free light chains (FLC) assay: Involved FLC level ≥ 10 mg\u002Fdl (≥ 100 mg\u002Fl) and serum free light chain ratio is abnormal.\n* Two or more prior lines of therapies, triple-class exposed (exposed \u002Frefractory to an immunodulatory derivative (IMiD) and\u002For proteasome inhibitors (PI) and\u002For to daratumumab or other anti-CD38 monoclonal antibody).\n* No prior exposure to iberdomide or belamaf.\n* No prior BCMA-directed therapy.\n* No prior treatment with a monoclonal antibody within 2 weeks of registration.\n* No history of severe allergic reaction (including erythema nodosum) to lenalidomide, pomalidoimide or other prior IMiD therapy.\n* No prior allogeneic stem cell transplant. NOTE: Participants who have undergone syngeneic transplant will be allowed only if no history of or no currently active GvHD.\n* Participant must not have received a live or live-attenuated vaccine within 30 days prior to registration.\n* No plasmapheresis within 7 days prior to registration.\n* Age ≥ 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n* Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm\\^3.\n* Platelet count ≥ 75,000\u002Fmm\\^3 (or ≥ 50,000\u002Fmm\\^3 in Phase II if bone marrow (BM) plasma cells \\> 50%).\n* Calculated (Calc.) creatinine clearance ≥ 30 mL\u002Fmin using Cockcroft-Gault equation.\n* Spot urine (albumin\u002Fcreatinine ratios) \\\u003C 500 mg\u002Fg (56 mg\u002Fmmol) OR urine dipstick ≥ 1+ if confirmed.\n* Total bilirubin ≤ 2 mg\u002FdL.\n* Aspartate aminotransferase (AST)\u002Falanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN).\n* Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effect on the developing fetus and newborn are unknown. FCBP (female of childbearing potential) is a female who: 1) has achieved menarche (first menstrual cycle) at some point, 2) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months). Women of childbearing potential (WOCBP):\n\n  * Must use a contraceptive method that is highly effective (with a failure rate of \\\u003C 1% per year), preferably with low user dependency during the intervention period and for at least 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.\n  * The effects of iberdomide on the developing human fetus are unknown. Immunodulatory derivative (IMiD) agents as well as other therapeutic agents used in this trial are known to be teratogenic. Females of child-bearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU\u002FmL within 10-14 days prior to, and again within 24 hours of starting iberdomide, and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective method at the same time, at least 28 days before she starts taking iberdomide. Examples of highly effective methods are intrauterine device, hormonal contraceptives, tubal ligation, or partner's vasectomy. Examples of barrier method are male condom, diaphragm, or cervical cap. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risk of fetal exposure.\n  * Should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study, she should inform her treating physician immediately. FCBP must use adequate contraception for at least 4 months after discontinuation from study. Because of the potential for serious adverse reactions in a breastfed child, women are advised not to breastfeed during treatment and for at least 3 months after the last dose.\n  * The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with a nearly undetected pregnancy. Nonchildbearing potential is defined as follows (by other than medical reasons):\n  * ≥ 45 years of age and has not had menses for \\> 1 year\n  * Patients who have been amenorrhoeic for \\\u003C 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation\n  * Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.\n  * Male patients must agree to use an adequate method of contraception for the duration of the study and for 6 months afterwards.\n  * Male participants: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies: Male participants are eligible to participate if they agree to the following during the intervention period and for 6 months after the last dose of study treatment to allow for clearance of any altered sperm:\n  * Refrain from donating sperm PLUS, either:\n  * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR\n  * Must agree to use contraception\u002Fbarrier as detailed below:\n  * Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of \\\u003C 1% per year as when having sexual intercourse with a woman of childbearing potential (including pregnant females).\n* Archival tissue must be available for submission for the mandatory correlative studies.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n\n  \\* Patients with treated brain metastases are eligible if follow up brain imaging after central nervous system (CNS) directed therapy shows no evidence of progression.\n* No patients with uncontrolled human immunodeficiency virus (HIV), hepatitis C and B. Testing for HIV and hepatitis C and B are not required prior to registration.\n\n  \\* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n* No positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to registration unless the participant can meet the following criteria:\n\n  * RNA test negative.\n  * Successful anti-viral treatment (usually 8 weeks duration) is required, followed by a negative hepatitis C virus (HCV) RNA test after a washout period of at least 4 weeks.\n* Patients with hepatitis B will be excluded unless the following criteria can be met.\n\n  * Serology: Hepatitis B core antibody positive (HbcAb)+, hepatitis B surface antigen (HbsAg)-.\n  * Screening: Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) undetectable.\n  * During study treatment: Monitoring per protocol.\n  * During study treatment: Antiviral treatment instituted if HBV DNA becomes detectable.\n  * Serology: HBsAg+ at screen or within 3 months prior to registration.\n  * Screening: HBV DNA undetectable.\n  * Screening: Highly effective antiviral treatment started at least 4 weeks prior to first registration.\n  * Screening: Baseline imaging per protocol.\n  * Screening: Participants with cirrhosis are excluded.\n  * During study treatment: Antiviral treatment maintained throughout study treatment.\n  * During study treatment: Monitoring and management per protocol. \\*\\* Note: Presence of isolated hepatitis (Hep) B surface antibody (HBsAb) indicating previous vaccination will not exclude a participant.\n* No patients with unacceptable cardiac risk factors defined by any of the following criteria:\n\n  * Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant electrocardiogram (ECG) abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block.\n  * History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within three (3) months of Screening.\n  * Class III or IV heart failure as defined by the New York Heart Association functional classification system \\[Error! Reference source not found., 1994\\].\n  * Uncontrolled hypertension.\n  * Patients with congenital long QT syndrome, QTcF interval QTcF \\> 480 msec (the QT interval values must be corrected for heart rate by Fridericia's formula \\[QTcF\\]).\n  * Any history of ventricular fibrillation or torsade de pointes.\n  * Symptomatic bradycardia defined as heart rate (HR) \\\u003C 50 bpm with associated dizziness\u002Fsyncope.\n  * Left ventricular ejection fraction \\\u003C 30%.\n* No patients who have received targeted (non-monoclonal antibodies \\[mAb\\]) or investigational agents within 2 weeks prior to rgistration and who have not recovered from side effects of those therapies.\n* No patients who have undergone major surgery ≤ 2 weeks prior to registration or who have not recovered from the side-effects of surgery.\n* No known medical condition causing an inability to swallow oral formulations of agents.\n* No active bacterial, viral or fungal infection (s) present.\n* Patients cannot have a Child-Pugh score greater than 1 (absent ascites, total bilirubin \\\u003C 2, international normalized ratio (INR) \\\u003C1.7 (unless on anticoagulation), and no encephalopathy; esophageal or gastric varices, and cirrhosis. Note: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if otherwise meets entry criteria.\n* No presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM are eligible, provided they fulfill inclusion criteria.\n* No evidence of active mucosal or internal bleeding.\n* No known immediate or delayed hypersensitivity reaction or idiosyncratic reactions to belamaf or drugs chemically related to belamaf, or any of the components of the study treatment.\n* Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, skin changes) or active plasma cell leukemia at the time of screening.\n* Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study. Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 14 days prior to the start of study treatment. Participant must not have current corneal epithelial disease except mild changes in corneal epithelium. For belantamab mafodotin, concomitant administration with strong inhibitors of OATP should be avoided.\n* RE-REGISTRATION ELIGIBILITY CRITERIA: Patients must meet criteria for progression of myeloma as defined by IMWG criteria indicated as any of the following:\n\n  * ≥ 25% increase in M-protein (must be at least 0.5 g\u002Fdl above nadir from last treatment regimen).\n  * 25% difference between involved and uninvolved serum free light chains from its nadir or\n  * The development of new plasmacytomas or hypercalcemia not due to other causes. In the absence of progression by serum M protein or free light chain, biopsy of new plasmacytoma of extramedullary disease is warranted.\n  * If refractory myeloma, it should be defined by IMWG criteria as disease which has become non-responsive or progressive on belamaf\u002Fdexamethasone.\n* RE-REGISTRATION ELIGIBILITY CRITERIA: Measurable disease defined by IMWG criteria as:\n\n  * Serum M-protein ≥ 0.5 g\u002FdL.\n  * Urine monoclonal protein ≥ 200 mg\u002F24h.\n  * Serum FLC assay: Involved FLC level ≥ 10 mg\u002Fdl (≥ 100 mg\u002Fl) and serum free light chain ratio is abnormal.\n  * PET\u002FCT or MRI findings consistent with (c\u002Fw) disease progression.\n* RE-REGISTRATION ELIGIBILITY CRITERIA: Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm\\^3.\n* RE-REGISTRATION ELIGIBILITY CRITERIA: Platelet Count ≥ 75,000\u002Fmm\\^3 (or ≥ 50,000\u002Fmm\\^3 if BM plasma cells \\> 50%).\n* RE-REGISTRATION ELIGIBILITY CRITERIA: Calc. creatinine clearance ≥ 30 mL\u002Fmin using Cockcroft-Gault equation.\n* RE-REGISTRATION ELIGIBILITY CRITERIA: Total bilirubin ≤ 2 mg\u002FdL.\n* RE-REGISTRATION ELIGIBILITY CRITERIA: AST\u002FALT ≤ 2.5 x upper limit of normal (ULN).\n* RE-REGISTRATION ELIGIBILITY CRITERIA: Alkaline phosphatase ≤ 3 x ULN.","ALL","18 Years",{"count":19,"type":20},88,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This phase I\u002FII trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Multiple myeloma is a cancer that affects white blood cells called plasma cells, which are made in the bone marrow and are part of the immune system. Multiple myeloma cells have a protein on their surface called B-cell maturation antigen (BCMA) that allows the cancer cells to survive and grow. Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Belantamab mafodotin has been designed to attach to the BCMA protein, which may cause the myeloma cell to become damaged and die. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Iberdomide plus belantamab mafodotin may help slow or stop the growth of cancer in patients with multiple myeloma.",[27,28],"Recurrent Multiple Myeloma","Refractory Multiple Myeloma","RECRUITING","2026-07-01",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":33},"2025-04-23",{"date":37,"type":20},"2030-08-01",{"name":39,"class":40},"Alliance for Clinical Trials in Oncology","OTHER",42,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100551840","phase-1-testing-teclistamab-tecvayli-in-combination-with-iberdomide-for-relapsed-or-refractory-multiple-myeloma-100551840","NCT06465316","Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma","A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed multiple myeloma (MM), as defined in the International Myeloma Working Group (IMWG) criteria\n* If patients have undergone autologous stem cell transplant (SCT), day 0 of SCT must be \\> 100 days to be eligible for the study\n* Patients must have had disease progression after ≥ 4 prior lines of anti-myeloma treatments including one proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib), one immunomodulatory imide drug (ImiD) (e.g., thalidomide, lenalidomide, pomalidomide \\[POM\\]), and one anti-CD38 monoclonal antibody (e.g., daratumumab, isatuximab)\n* Patients must have measurable disease, defined as:\n\n  * Serum M-protein ≥ 0.5 g\u002FdL (≥ 5 g\u002FL)\n  * Urine M-protein ≥ 200 mg\u002F24 h\n  * Serum free light chain (FLC) assay: \"involved\" FLC level ≥ 10 mg\u002FdL (≥ 100 mg\u002FL) and an abnormal serum free light chain ratio (\\\u003C 0.26 or \\> 1.65)\n  * Note: Patients with non-secretory disease will be allowed to participate\n* Age ≥ 18 years\n\n  * Because no dosing or adverse event data are currently available on the use of iberdomide in combination with teclistamab in patients \\\u003C 18 years of age, children are excluded from this study\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60)\n* Hemoglobin ≥ 7.0 g\u002FdL (≤ 28 days prior to registration) (Without growth factor support, blood transfusion, or platelet stimulating agents for the past 7 days, excluding erythropoietin)\n* Absolute neutrophil count ≥ 1,000\u002FmcL (≤ 28 days prior to registration) (Without growth factor support, blood transfusion, or platelet stimulating agents for the past 7 days, excluding erythropoietin)\n* Platelets ≥ 50,000\u002FmcL (≤ 28 days prior to registration) (Without growth factor support, blood transfusion, or platelet stimulating agents for the past 7 days, excluding erythropoietin)\n* Total bilirubin ≤ 2 x institutional upper limit of normal (ULN) (≤ 28 days prior to registration)\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 3 x institutional ULN (≤ 28 days prior to registration)\n* Estimated glomerular filtration rate (eGFR) \\> 30 mL\u002Fmin (≤ 28 days prior to registration)\n* Spot urine (albumin\u002Fcreatine ratio) ≤ 500mg\u002Fg (56 mg\u002Fmmol) OR urine dipstick negative\u002Ftrace (if \\> 1+ only eligible if confirmed ≤ 500 mg\u002Fg (56 mg\u002Fmmol) by albumin\u002Fcreatinine ratio (spot urine from first void) (≤ 28 days prior to registration)\n* Note: Laboratory results obtained during screening should be used to determine eligibility criteria. In situations where laboratory results are outside the permitted range, the investigator may re-test the subject and the subsequent within range screening result may be used to confirm eligibility\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients with treated brain metastases are eligible if follow-up brain imaging done a minimum of 28 days after completion of central nervous system (CNS)-directed therapy shows no evidence of progression\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better\n* Based on the mechanism of action, teclistamab may cause fetal harm when administered to a pregnant woman. Females of child-bearing potential (FCBP): should use effective contraception during treatment with teclistamab and for 5 months after the last dose. FCBP should not breast feed during treatment with teclistamab and for 5 months after the last dose. Should a FCBP become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. The effects of iberdomide on the developing human fetus are unknown. However, IMiDs are known to be teratogenic. FCBP must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU\u002FmL within 10-14 days prior to starting iberdomide, and again within 24 hours. FCBP must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control-one highly effective method and one additional effective method-at the same time, at least 28 days before starting iberdomide, while taking iberdomide, and for 28 days following discontinuation from the study. Examples of highly effective methods are intrauterine device, hormonal contraceptives, tubal ligation, or partner's vasectomy. Examples of barrier method are male condom, diaphragm, or cervical cap. FCBP must also agree to ongoing pregnancy testing. Men must practice complete abstinence or agree to use a condom during sexual contact with FCBP while participating in the study, during dose interruptions, and for at least 28 days following discontinuation from the study, even if he has undergone a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risk of fetal exposure\n* Men must agree to abstain from donating and semen or sperm while taking iberdomide, during dose interruptions, and for at least 28 days after the last dose of iberdomide. FCBP must agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period\n* All patients must agree to abstain from donating blood products while taking iberdomide and for at least 28 days after the last dose of iberdomide\n* Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study subjects\n* Willingness to adhere to the study visit schedule and other protocol requirements and provide mandatory blood and bone marrow specimens for correlative research\n* Willingness to return to the enrolling institution for follow-up\n\nExclusion Criteria:\n\n* Patients who have active plasma cell leukemia, active amyloid light chain (AL) (primary) amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, myeloma protein, and skin changes), and Waldenstrom macroglobulinemia are ineligible\n* If a patient develops recurrent\u002Frefractory (R\u002FR) disease while receiving the most recent line of therapy, there is no need for a washout period\n* Patients who have had prior anti-BCMA directed bispecific antibody (BsAb) therapy exposure (prior treatment with anti-BCMA directed antibody drug conjugate, anti-BCMA-directed chimeric antigen receptor (CAR) T cell therapy, and prior non-BCMA-targeting BsAb are permitted)\n* Patients who have had prior treatment with a cereblon E3 ligase modulator, including mezigdomide, iberdomide, and CFT7455 (all currently in clinical development)\n* Patients who received plasmapheresis ≤ 7 days prior to registration\n* Patients who received a prior allogeneic SCT. Autologous SCT is allowed\n* Patients who received a live or live-attenuated vaccine ≤ 30 days prior to registration. Patients are allowed to receive a coronavirus disease 2019 (COVID-19) vaccine at any timepoint during protocol treatment\n* Systemic active infection requiring treatment\n* Any unresolved toxicity ≥ grade 2 from previous treatment except for alopecia or peripheral neuropathy up to grade 2\n* Patients who have had any major surgery ≤ 4 weeks prior to registration\n* Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make this protocol unreasonably hazardous\n* Patients with evidence of active mucosal or internal bleeding\n* Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Stable chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if participant otherwise meets entry criteria\n* Patients with known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to teclistamab or iberdomide, or any of the components of the study treatment\n* Patients who are taking any anticancer therapy other than hormonal therapy (for prostrate or breast cancer) and palliative radiotherapy (defined as radiation to ≤ 3 sites of active multiple myeloma)\n* Patients who require immunosuppressive medications including, but not limited to, systemic corticosteroids at doses exceeding 10 mg\u002Fday of prednisone or equivalent. Use of immunosuppressive medications for the management of iberdomide-related adverse events (AEs) or in subjects with contrast allergies is acceptable. In addition, use of inhaled, topical, intranasal corticosteroids or local steroid injection (e.g., intra-articular injection) is permitted. Temporary use of corticosteroids for concurrent illnesses (e.g., food allergies, computed tomography \\[CT\\] scan contrast hypersensitivity, pneumonia, etc.) are acceptable\n* Patients who require medications that are strong inhibitors or inducers of CYP3A4\u002F5\n* Patients who are receiving any other investigational agents\n* Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous\n* Pregnant women are excluded from this study because iberdomide is a thalidomide analog and thalidomide is a known human teratogen. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with iberdomide, breastfeeding should be discontinued if the mother is treated with iberdomide. These potential risks may also apply to other agents used in this study\n* Patients who are unable or unwilling to undergo protocol required thromboembolism prophylaxis are excluded",{"count":50,"type":20},26,[23],"This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to survive. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as teclistamab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving iberdomide in combination with teclistamab may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma.",[27,28],"2026-06-27",{"date":56,"type":33},"2026-06-30",{"date":58,"type":33},"2024-12-06",{"date":60,"type":20},"2026-12-31",{"name":62,"class":63},"National Cancer Institute (NCI)","NIH",14,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":4},"100628605","phase-1-testing-the-investigational-medication-combination-of-teclistamab-and-pomalidomide-compared-to-the-usual-treatment-carfilzomib-pomalidomide-and-dexamethasone-for-patients-with-multiple-myeloma-who-have-relapsed-shortly-after-treatment-100628605","NCT07463807","Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","Phase Ib\u002FII Fixed Duration Study of Teclistamab\u002FPomalidomide (TP) Versus Carfilzomib\u002FPomalidomide\u002FDexamethasone (KPd) in Early Relapse of Multiple Myeloma","Inclusion Criteria:\n\n* Patient must be ≥ 18 years of age\n* Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Patient must have an identifiable dominant sequence (clonotype) established based on Adaptive Biotechnologies clonoSEQ® assay for Phase II only\n* Patient must have multiple myeloma and meet both of the following criteria for the original diagnosis of myeloma following the International Myeloma Working Group (IMWG) myeloma diagnostic criteria:\n\n  * Bone marrow plasmacytosis with ≥ 10% plasma cells or sheets of plasma cells or biopsy proven plasmacytoma.\n\n    * Tissue biopsy of any bone lesion or extramedullary plasmacytoma if applicable (positive\u002Fnegative for clonal plasma cells)\n  * Any one or more of the following symptomatic myeloma-defining events that prompted initiation of therapy as well as end-organ damage:\n\n    * Anemia (hemoglobin value of \\> 2 g\u002FdL below the lower limit of normal, or a hemoglobin value \\\u003C 10 g\u002FdL)\n    * Hypercalcemia (serum calcium \\> 1 mg\u002FdL higher than the upper limit of normal or \\> 11 mg\u002FdL)\n    * Bone disease (one or more osteolytic lesions on skeletal radiography, CT, or FDG-PET\u002FCT)\n    * Renal dysfunction (creatinine clearance \\\u003C 40 mL\u002Fmin or serum creatinine \\> 2 mg\u002FdL).\n    * Clonal bone marrow plasma cells (BMPCs) ≥ 60%\n    * Involved\u002Funinvolved serum free light chain ratio ≥ 100\n    * \\> 1 focal lesions on magnetic resonance imaging (MRI) studies ≥ 5 mm\n  * NOTE: Patients with smoldering myeloma (serum m protein ≥ 3 gm\u002FdL or bone marrow plasma cells ≥ 10% or greater plus no evidence of anemia, hypercalcemia, lytic bone lesions or renal dysfunction) and monoclonal gammopathy of undetermined significance (serum m protein \\\u003C 3 gm\u002FdL and bone marrow plasma cells \\\u003C 10% or greater plus no evidence of anemia, hypercalcemia, lytic bone lesions or renal dysfunction) are not eligible\n* Patient must have experienced early relapse disease defined as relapse after one line of lenalidomide therapy including single agent lenalidomide or lenalidomide\u002Fdexamethasone or CD38 antibody\u002Flenalidomide +\u002F- dexamethasone. The relapse can be progressive disease as determined by the treating clinician and meeting measurable disease criteria\n* Patient must have received no more than two lines of IMWG defined therapy (induction +\u002F- transplant + maintenance is considered a single line of therapy)\n* Patient must not receive non-protocol concurrent chemotherapy for the study disease, or any ancillary therapy considered investigational while participating in the study\n* Patient must have received an immunomodulatory drug (lenalidomide) and a CD38 antibody (daratumumab or isatuximab)\n* Patient must have measurable disease as defined by having one or more of the following, obtained within 28 days prior to registration\u002Frandomization:\n\n  * ≥ 0.5 g\u002FdL monoclonal protein (M-protein) on serum protein electrophoresis\n  * ≥ 200 mg\u002F24 hrs of monoclonal protein (M-protein) on a 24-hour urine protein electrophoresis\n  * Involved free light chain ≥ 10 mg\u002FdL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (\\\u003C 0.26 or \\> 1.65)\n  * Exception: patients without measurable disease in the serum or urine, but with bone or soft tissue plasmacytoma(s) ≥ 2 cm or who have bone marrow plasma cells ≥ 30% are eligible on study\n  * NOTE: Urine protein electrophoresis (UPEP) (on a 24 hour collection) is required, no substitute method is acceptable. Urine must be followed monthly if the baseline urine M-spike is ≥ 200 mg\u002F24 hr. Please note that if both serum and urine m-components are present, both must be followed in order to evaluate response.\n* Patient must not be known to be refractory to carfilzomib or pomalidomide\n* Patient must not have received a prior BCMA therapy\n* Patient must not be pregnant due to the potential harm to an unborn fetus with the treatment regimens being used\n\n  * All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration\u002Frandomization to rule out pregnancy. Patients must also agree to a second pregnancy test completed within 24 hours prior to the first dose of pomalidomide and teclistamab and agree to ongoing pregnancy testing while on protocol treatment\n  * A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria:\n\n    * Has achieved menarche at some point\n    * Has not undergone a hysterectomy or bilateral oophorectomy\n    * Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\n* Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 6 months after the last dose of protocol treatment for patients on Arms A, B, and C and for 1 month after the last dose of protocol treatment for patients on Arm D. In addition, all patients must also agree to register to the mandatory Risk Evaluation and Mitigation Strategies (REMS)® program and be willing and able to comply with the requirements of the REMS® program\n* Patient must agree to not breastfeed while on protocol treatment due to the potential risk for adverse events in nursing infants, and must agree to continue not breastfeeding for an additional 5 months after the last dose of Arm A, B, or C protocol treatment and for an additional 28 days after the last dose of Arm D protocol treatment\n* Patient must agree to abstain for donating eggs (ova, oocytes) while on study treatment and for 6 months after the last dose of Arm A, B or C protocol treatment\n* Patient must agree to abstain from donating sperm while on study treatment and for 3 months after the last dose of protocol treatment even if they have had a successful vasectomy\n* Patient must agree to abstain from donating blood during study participation and for at least 28 days after the last dose of protocol treatment\n* Patient must not receive non-protocol concurrent chemotherapy, or any ancillary therapy considered investigational while participating in the study\n\n  * NOTE: Bisphosphonates are considered supportive care rather than therapy and are thus allowed while on protocol treatment\n* Patient must not have peripheral neuropathy \\> grade 2 on clinical examination at the time of registration\u002Frandomization\n* Patient must not have known uncontrolled congestive heart failure (CHF), New York Heart Association (NYHA) class III or IV, uncontrolled hypertension as defined as systolic \\> 180 and\u002For diastolic \\> 100, uncontrolled atrial (A) fib, or left ventricular ejection fraction (LVEF) \\\u003C 40% within 6 months prior to registration\u002Frandomization\n* Patient must not have known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients, or known sensitivity to mammalian-derived products\n* Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and\u002For family member available will also be considered eligible\n* Absolute neutrophil count (ANC) ≥ 1,500\u002FuL (≤ 14 days prior to registration\u002Frandomization)\n* Platelets ≥ 100,000\u002FuL (≤ 14 days prior to registration\u002Frandomization)\n* Total bilirubin ≤ 3 x institutional upper limit of normal (ULN) (≤ 14 days prior to registration\u002Frandomization)\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 3.0 x institutional ULN (≤ 14 days prior to registration\u002Frandomization)\n* Calculated creatinine clearance ≥ 30 mL\u002Fmin (≤ 14 days prior to registration\u002Frandomization)\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration\u002Frandomization are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients with past central nervous system (CNS) involvement are eligible if there is no current CNS involvement\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial",{"count":73,"type":20},162,[23,24],"This phase Ib\u002FII trial compares the effect of teclistamab and pomalidomide to standard treatment with carfilzomib, pomalidomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen (BCMA), a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Pomalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Carfilzomib blocks the action of enzymes called proteasomes, which may help keep cancer cells from growing and may kill them. It is a type of proteasome inhibitor. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving teclistamab and pomalidomide may be safe, tolerable and improve response by lowering myeloma cells to undetectable levels when compared to standard treatment with carfilzomib, pomalidomide and dexamethasone in treating patients with relapsed multiple myeloma.",[27,28],"NOT_YET_RECRUITING","2026-06-26",{"date":80,"type":33},"2026-06-29",{"date":82,"type":20},"2026-07-24",{"date":84,"type":20},"2026-08-31",{"name":62,"class":63},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100576447","phase-1-elotuzumab-daratumumab-iberdomide-and-dexamethasone-for-the-treatment-of-relapsed-multiple-myeloma-100576447","NCT06785415","Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma","Phase 1\u002F2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of signing the informed consent form (ICF).\n* Diagnosis of relapsed multiple myeloma with ≤ 3 prior lines of therapy including treatment with proteasome inhibitors (i.e., ixazomib, carfilzomib, bortezomib), immunomodulatory imide drugs (i.e., lenalidomide, pomalidomide), and anti-CD38 drugs (i.e., daratumumab, isatuximab). Patients are required to have received a proteasome inhibitor, immunomodulatory imide drug, or combination of the two drug classes during first-line treatment.\n\n  * Note: Prior treatment with iberdomide is not allowed. Patients should not be refractory simultaneously to all other drugs in the combination.\n* Measurable disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2.\n* Hemoglobin ≥ 8.0 g\u002FdL (obtained ≤14 days prior to registration).\n* Absolute neutrophil count (ANC) ≥ 1000\u002Fm\\^3 (obtained ≤14 days prior to registration).\n* Platelet count ≥ 50,000\u002Fmm\\^3. Note: It is not permissible to transfuse subjects to achieve minimum platelet counts (obtained ≤14 days prior to registration).\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (≤ 3 x ULN for patients with Gilbert's syndrome) (obtained ≤14 days prior to registration).\n* Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2 x ULN and alkaline phosphatase ≤ 1.5 x ULN (obtained ≤14 days prior to registration).\n* Calculated creatinine clearance ≥ 30 ml\u002Fmin using the Cockcroft-Gault (obtained ≤14 days prior to registration).\n* Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only. Note: A person of childbearing potential (PCBP) is a person who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) and must:\n\n  * Have 2 negative pregnancy tests prior to starting study treatment and must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence from heterosexual contact.\n\nAND\n\n* Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with two forms of contraception: one highly effective, and one additional effective (barrier) measure of contraception without interruption 28 days prior to starting investigational product, during the study treatment, and for at least 28 days after the last dose of iberdomide, 90 days after the last dose of daratumumab, 7 months after last dose of elotuzumab whichever is longer.\n* NOTE: Non-childbearing potential is defined as follows (by other than medical reasons):\n\n  * ≥ 45 years of age and has not had menses for \\> 24 months.\n  * Patients who have been amenorrhoeic for \\\u003C 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation.\n  * Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.\n\n    * Willingness to follow Pregnancy Prevention Program requirements:\n* Persons of childbearing potential must agree to use a contraceptive method that is highly effective (with a failure rate of \\\u003C 1% per year), preferably with low user dependency, during the intervention period and for at least 7 months after the last dose of study intervention. These patients must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period.\n* Persons able to father a child must agree that during the treatment intervention period and for 6 months after the last dose of study treatment (to allow for clearance of any altered sperm), the participant will:\n\n  * Refrain from donating sperm while on study treatment, during dose interruptions and for at least 6 months following last dose of study treatment, PLUS either:\n  * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, OR,\n  * Must agree to use contraception\u002Fbarrier such as a male condom (even if they have undergone successful vasectomy), and when having sexual intercourse with a person of childbearing potential who is not currently pregnant his partner will use an additional highly effective contraceptive method with a failure rate of \\\u003C 1% per year.\n\n    * Provide written informed consent.\n    * Willingness to provide mandatory bone marrow specimens for correlative research.\n    * Willing and able to adhere to the study visit schedule and other protocol requirements. Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).\n    * Willing to refrain from donating blood while on study treatment, during dose interruptions and for at least 28 days following the last dose of study treatment.\n\nExclusion Criteria:\n\n* Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:\n\n  * Pregnant persons\n  * Nursing persons\n  * Men or women of childbearing potential who are unwilling to employ adequate contraception.\n* Receiving any other concurrent chemotherapy, or any ancillary therapy considered investigational.\n\n  * Note: Bisphosphonates are supportive care rather than therapy and are thus allowed while on protocol treatment.\n* Known to be human immunodeficiency virus (HIV) positive known or suspected active hepatitis C infection or seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen \\[HBsAg\\]) at registration or ≤ 3 months prior to registration.\n\n  * Note: Participants with resolved hepatitis B infection (i.e., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen \\[anti-HBc\\] and\u002For antibodies to hepatitis B surface antigen \\[anti-HBs\\]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded.\n  * EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.\n* Evidence of cardiovascular disease risk, as defined by any of the following:\n\n  * Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant electrocardiogram (ECG) abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block\n  * History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting ≤ three (3) months prior to registration.\n  * Class III or IV heart failure as defined by the New York Heart Association functional classification system \\[NYHA, 1994\\]\n  * Uncontrolled hypertension\n  * History of life-threatening ventricular arrhythmias.\n* Known moderate or severe persistent asthma, or currently has uncontrolled asthma of any classification.\n* Unable or unwilling to undergo protocol required thromboembolism prophylaxis.\n* Has taken a strong inhibitor or inducer of CYP3A4\u002F5 including grapefruit, St. John's Wort or related products ≤ 14 days prior to registration.\n* Known allergy to any of the study medications, their analogues or excipients in the various formulations.\n* Major surgery ≤ 14 days prior to registration.\n* Has been treated with an investigational agent (i.e., an agent not commercially available) ≤ 28 days or 5 half-lives (whichever is longer) prior to registration.\n* Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.\n* Any co-morbidity which would interfere with patient's ability to participate in trial, e.g. uncontrolled infection, uncompensated heart or lung disease.\n* History of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, or pomalidomide.\n* Peripheral neuropathy grade ≥ 2.\n* Severe acute respiratory syndrome coronavirus 2 infection ≤ 14 days prior to registration for mild or asymptomatic infections OR ≤ 28 days prior to registration for severe\u002Fcritical illness.\n* Gastrointestinal disease that may significantly alter the absorption of iberdomide.\n* Received a live vaccine ≤ 90 days prior to registration.\n* Prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥ 5 years with the exception of the following noninvasive malignancies:\n\n  * Basal cell carcinoma of the skin\n  * Squamous cell carcinoma of the skin in situ (stage 0)\n  * Carcinoma in situ of the cervix\n  * Carcinoma in situ of the breast\n  * Incidental histologic finding of prostate cancer (T1a or T1b using the TNM \\[tumor, nodes, metastasis\\] clinical staging system) or prostate cancer that is curative.\n* Received hydroxychloroquine, quinacrine, chloroquine, methotrexate, leflunomide, sulfasalazine, mycophenolate mofetil, mycophenolic acid ≤ 28 days prior to registration.\n* Received daily nonsteroidal anti-inflammatory drugs (NSAIDs) ≤ 14 days prior to registration. Note: Allowed if dose has been stable for at least 14 days.\n* Received immunomodulating or immunosuppressive therapy as follows:\n\n  * Etanercept ≤ 28 days prior to registration\n  * Belimumab ≤ 12 weeks prior to registration\n  * B-cell depleting or modulating agents (such as rituximab or anti-CD22 therapy) ≤ 365 days prior to registration.",{"count":94,"type":20},37,[23,24],"This phase I\u002FII trial tests the safety, side effects, and best dose of iberdomide and how well it works in combination with daratumumab, elotuzumab, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Elotuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving iberdomide in combination with daratumumab, elotuzumab, and dexamethasone may be safe, tolerable and\u002For effective in patients with relapsed multiple myeloma.",[27],"2026-06-22",{"date":100,"type":33},"2026-06-25",{"date":102,"type":33},"2025-03-18",{"date":104,"type":20},"2031-04-01",{"name":106,"class":40},"Mayo Clinic",1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":107},"100641459","phase-2-infliximab-for-cytokine-release-syndrome-prophylaxis-during-teclistamab-or-talquetamab-therapy-in-patients-with-relapsed-or-refractory-myeloma-100641459","NCT07657312","Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma","Phase 2 Study of Cytokine Release Syndrome Prophylaxis With Infliximab for Teclistamab\u002FTalquetamab Therapy in Patients With Relapsed\u002FRefractory Myeloma","Inclusion Criteria:\n\n* Patients 18 years of age or older with evidence of relapsed or refractory disease as defined by IMWG criteria and measurable disease as defined by any of the following:\n\n  * Serum M-protein ≥ 0.5 g\u002Fdl\n  * Urine monoclonal protein ≥ 200 mg\u002F24h\n  * Involved free light chain (FLC) level ≥ 10mg\u002Fdl (≥ 100mg\u002Fl) and an abnormal serum free light chain ratio (\\\u003C 0.26, or \\> 1.65)\n* Patients must have had at least 4 prior lines of therapy including an immunomodulatory agent (IMID), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody.\n\n  * Prior B-cell maturating antigen (BCMA) chimeric antigen receptor (CAR)-T is permitted but at least 6 months must have lapsed from CAR-T exposure\n  * Prior tumor necrosis factor alpha (TNFα) inhibitor use for a concomitant condition (ex. Rheumatoid arthritis) is permitted but at least 6 months must have lapsed from exposure\n* Patients must have hemoglobin ≥ 7g\u002FdL\n* Absolute neutrophil count (ANC) ≥ 1000\u002FµL\n* Platelets ≥ 50,000\u002FµL\n* Total bilirubin ≤ 1.5 X the upper limit of normal (ULN)\n* Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase \\\u003C 2.5 X the ULN\n* Calculated creatinine clearance of ≥ 30ml\u002Fmin using Modification of Diet in Renal Disease (MDRD) formula\n* Patients must have adequate cardiac function as evidenced by:\n\n  * Left ventricular ejection fraction ≥ 30%; baseline echocardiography (ECHO) is not required if ECHO was done within the preceding 6 months and patients do not have new signs\u002Fsymptoms suggestive of heart failure\n  * No uncontrolled arrhythmias\n  * No New York Heart Association class III-IV heart failure\n  * 12-lead electrocardiogram (ECG) with QT interval calculated by Fridericia Formula (QTcF) interval of ≤ 470 msec\n* Negative test result for latent tuberculosis at screening\n* Patients must provide informed consent\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of ≤ 2\n* Fertility requirements\n\n  * Women of child bearing potential (WOCBP) must commit to either abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously. This includes one highly effective form of contraception (tubal ligation, intrauterine device \\[IUD\\], hormonal \\[birth control pills, injections, hormonal patches, vaginal rings or implants\\] or partner's vasectomy) and one additional effective contraceptive method (male latex or synthetic condom, diaphragm, or cervical cap). Contraception must begin 4 weeks prior to dosing and continue to 6 months after study treatment ending or teclistamab\u002Ftalquetamab ending, whichever is longer. Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy\n  * Investigators shall counsel WOCBP and male participants who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy\n  * A negative pregnancy test will be required for all WOCBP at screening and within 24 hours before starting treatment drugs, and with each cycle\n  * Breast feeding is not permitted\n  * Male patients must agree to use an adequate method of contraception (latex or synthetic condom) for the duration of the study and up to 6 months after study treatment ending\n  * Criteria also applies to azoospermic males\n  * Males should refrain from sperm donation during this time and continue for 6 months after study treatment ending\n\nExclusion Criteria:\n\n* Patients with Waldenstrom macroglobulinemia, primary amyloid light chain (AL) amyloidosis, primary plasma cell leukemia, or polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome\n* Patients receiving concurrent corticosteroids at the time protocol therapy is initiated other than for physiologic maintenance treatment\n* Concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and antitumor activity of the study drugs\n* Live vaccines should not be given concurrently with infliximab. Vaccination with live virus vaccines is not recommended for at least 4 weeks prior to the start of treatment, during treatment and least 4 weeks after treatment\n* Clinically active rheumatoid arthritis (RA), psoriatic arthritis (PsA), and\u002For ankylosing spondylitis (AS), or concurrent use of abatacept, anakinra, rituximab, or other biologic products approved to treat these diseases within the preceding 6 months\n* Patients with history of anaphylaxis or hypersensitivity to etanercept, infliximab, adalimumab, certolizumab pegol, or golimumab\n* Unacceptable respiratory risk factors defined by any one of the following criteria:\n\n  * Chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) less than 50% of predicted normal\n  * Moderate or severe persistent asthma within the past 2 years, or currently has uncontrolled asthma of any classification\n* Unacceptable cardiac risk factors defined by any of the following criteria:\n\n  * Left ventricular ejection fraction \\\u003C 30%\n  * Complete left bundle branch, bifascicular block or clinically significant abnormal electrocardiogram (EKG) finding at screening\n  * A prolongation of QT interval on Screening ECG as defined by repeated demonstration of a QTc interval \\> 470 msec using Fridericia's QT correction formula; a family history of Long QT Syndrome\n  * Myocardial infarction within 6 months\n  * Unstable angina\n* Unacceptable infectious risk factors defined by any of the following criteria:\n\n  * Active tuberculosis:\n\n    * History of active or latent tuberculosis (TB) before screening\n    * Any signs or symptoms suggestive of active TB upon medical history and\u002For physical examination\n    * Any known recent close contact with a person with active TB.\n  * Active invasive fungal infections\n  * Other active infections, including clinically important localized infections, and patients with a history of opportunistic infections\n* Unacceptable demyelinating neurologic risk factors including history or active multiple sclerosis, Guillain-Barre syndrome, optic neuritis, or peripheral demyelinating polyneuropathy\n* Patients who have received targeted or investigational agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is shorter) and who have not recovered from side effects of those therapies\n* Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from the side-effects of surgery\n* Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required\n* Patients with active hepatitis B (defined as hepatitis B surface antigen positive \\[HBsAg+\\]); hepatitis B virus (HBV) screening is required prior to beginning therapy\n\n  * Patients with prior hepatitis B vaccine are permitted (defined as hepatitis B surface antigen negative \\[HbsAg-\\], anti hepatitis B virus surface antibody positive \\[Anti-HBs+\\], anti hepatitis C virus surface antibody negative \\[Anti-HBc-\\])\n  * Non-active hepatitis B (HbsAg-, Anti-HBs+, Anti-HBc+) may be enrolled if on suppressive antiviral therapy and have no detectable viral load (additional monitoring for hepatitis B reactivation is advised)\n* Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention, other than non-melanoma skin cancer and carcinoma in situ of the cervix or breast, should not be enrolled\n* Patients with any significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to them by the study staff\n* Any other medical condition, including mental illness or substance abuse, deemed by the investigator(s) to likely interfere with the patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results",{"count":116,"type":20},35,[24],"This phase II trial tests how well giving infliximab works for the prevention of cytokine release syndrome (CRS) during treatment with teclistamab or talquetamab in patients with multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). CRS and neurologic toxicity (damage to the nervous system which includes the brain, spinal cord, and nerves) are potential risks of treatment with talquetamab and teclistamab. CRS involves a release of a large amount of proteins into the bloodstream causing inflammation. This may cause changes in blood pressure and heartbeat, flu-like symptoms (nausea, fever, and chills), and\u002For affect the lung\u002Fliver\u002Fkidney function. It may also cause certain brain-related symptoms, such as dizziness, weakness, confusion, difficulty speaking, and\u002For decreased brain function (possible paralysis and\u002For coma). Infliximab is a drug that prevents the tumor necrosis factor-alpha (TNF-α) from working. TNF-α is a cytokine, or chemical messenger, that helps your immune system produce inflammation. Giving infliximab may work well for the prevention of cytokine release syndrome during treatment with teclistamab or talquetamab in patients with relapsed or refractory multiple myeloma.",[120,27,28],"Cytokine Release Syndrome","2026-06-15",{"date":123,"type":33},"2026-06-18",{"date":125,"type":20},"2026-08-01",{"date":127,"type":20},"2027-12-31",{"name":129,"class":40},"Naresh Bumma",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":107},"100406984","phase-1-at-okt10-b10-and-fludarabine-alone-or-in-combination-with-cyclophosphamide-and-low-dose-tbi-before-donor-stem-cell-transplant-for-the-treatment-of-newly-diagnosed-recurrent-or-refractory-high-risk-multiple-myeloma-100406984","NCT04579523","²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma","A Phase I Trial Evaluating Escalating Doses of ²¹¹At-Labeled Anti-CD38 Monoclonal Antibody Followed by HLA-Matched or Haploidentical Donor Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma","Inclusion Criteria:\n\n* Patients with newly diagnosed or relapsed\u002Frefractory multiple myeloma\n* Patients with multiple myeloma must have at least one of the following high-risk features:\n\n  * t(4;14), t(14;16), t(14;20) or deletion 17p, gain in chromosome 1q (\\> 3 copies of CKS1b) by fluorescence in situ hybridization (FISH); hypodiploidy; complex karyotype\n  * Revised International Staging System III\n  * Plasmablastic morphology\n  * History of primary or secondary plasma cell leukemia\n* Patients must start ²¹¹At-OKT10-B10 within 40-180 days of autologous stem cell transplant (either as part of their induction, or as salvage)\n* Patients must have an estimated creatinine clearance greater than 50\u002Fml per minute measured by 24-hour urine collection\n* Total bilirubin \\\u003C 2 times the upper limit of normal\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 2 times the upper limit of normal)\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) =\\\u003C 2 or Karnofsky \\>= 70\n* Patients must have CD38+ myeloma cells as demonstrated by either flow cytometry or immunohistochemistry in most recent bone marrow that had evidence of clonal plasma cells\n* For patients of childbearing potential, must have a negative urinary pregnancy test on the day of and prior to infusion of ²¹¹At-OKT10-B10\n* Ability to provide informed consent\n* Patients must have an HLA-matched related donor or an HLA-matched unrelated donor who meets standard Fred Hutchinson Cancer Center and\u002For National Marrow Donor Program (NMDP) or other donor center criteria for peripheral blood stem cell (PBSC) or bone marrow donation, as follows:\n\n  * Related donor: related to the patient and genotypically or phenotypically identical for HLA-A, B, C, DRB1 and DQB1. Phenotypic identity must be confirmed by high-resolution typing\n  * Unrelated donor:\n\n    * Matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing; OR\n    * Mismatched for a single allele without antigen mismatching at HLA-A, B, or C as defined by high resolution typing but otherwise matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing\n    * Donors are excluded when preexisting immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment. The recommended procedure for patients with 10 of 10 HLA allele level (phenotypic) match is to obtain panel reactive antibody (PRA) screens to class I and class II antigens for all patients before HCT. If the PRA shows \\> 10% activity, then flow cytometric or B and T cell cytotoxic cross matches should be obtained. The donor should be excluded if any of the cytotoxic cross match assays are positive. For those patients with an HLA class I allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be obtained regardless of the PRA results. A positive anti-donor cytotoxic crossmatch is an absolute donor exclusion\n    * Patient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-allele mismatch, i.e., the patient is A\\*0101 and the donor is A\\*0102, and this type of mismatch is not allowed\n* Patients without an HLA-matched related or unrelated donor available must have a related donor who is identical for one HLA haplotype and mismatched at the HLA-A, -B or DRB1 loci of the unshared haplotype with the exception of single HLA-A, -B or DRB1 mismatches\n\nExclusion Criteria:\n\n* History of central nervous system involvement by multiple myeloma\n* Presence of circulating plasma cells in the peripheral blood of 5% or more by flow cytometry or morphology\n* Prior radioimmunotherapy or radiation of \\> 20 Gy to pelvis or at maximally tolerated levels to any critical normal organ\n* Prior allogeneic HCT\n* More than two prior autologous HCTs\n* Patients with plasmacytomas \\> 1 cm in bone marrow or any extramedullary plasmacytoma. Previously fludeoxyglucose F-18 (FDG) avid mass lesions by positron emission tomography (PET) that are no longer hypermetabolic following the most recent cycle of therapy are exempt, as are plasmacytomas irradiated with curative intent (\\>= 35 Gy)\n* Patients with symptomatic coronary artery disease defined as having angina or anginal equivalent, and\u002For arrhythmias requiring anti-arrhythmics for rhythm control\n* History of reactive airway disease and clinically significant asthma requiring ongoing treatment\n* Patients with the following organ dysfunction:\n\n  * Left ventricular ejection fraction \\\u003C 40% in patients with HLA-matched or unrelated donor or \\\u003C 45% in patients with an HLA-haploidentical donor\n  * New York Heart Association (NYHA) class \\> 1 heart failure\n  * Corrected diffusing capacity of the lungs for carbon monoxide (DLCO) \\\u003C 50% or receiving supplemental continuous oxygen. When pulmonary function tests cannot be obtained, the 6-minute walk test (6MWT, also known as exercise oximetry) will be used: Any patient with oxygen saturation on room air of \\\u003C 90% during a 6MWT will be excluded\n  * Liver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease\n* Patients who are known to be seropositive for human immunodeficiency virus (HIV)\n* Perceived inability to tolerate diagnostic or therapeutic procedures\n* Women of childbearing potential who are pregnant (beta-human chorionic gonadotropin \\[HCG\\]+) or breast feeding\n* Fertile men and women unwilling to use contraceptives during and for 12 months post-transplant\n* Uncontrolled or untreated active infection\n* Patients with known AL subtype amyloidosis\n* Inability to understand or give an informed consent\n* Known allergy to murine-based monoclonal antibodies\n* Known contraindications to radiotherapy\n* History of another primary malignancy that has not been in remission for at least 2 years. The following are exempt from the 2-year-limit: nonmelanoma skin cancer, curatively treated localized prostate cancer, or cervical carcinoma in situ or squamous intraepithelial lesion on papanicolaou (PAP) smear\n* Therapy with anti-CD38 monoclonal antibody within 3 months of ²¹¹At-OKT10-B10 infusion\n* Prior therapy with radiolabeled monoclonal antibodies\n* Any history of treatment with checkpoint inhibitor\u002Fs","70 Years",{"count":139,"type":20},30,[23],"This phase I trial investigates the side effects and best dose of ²¹¹At-OKT10-B10 when given together with fludarabine, alone or in combination with cyclophosphamide and low-dose total-body irradiation (TBI) before donor stem cell transplant in treating patients with high-risk multiple myeloma that is newly diagnosed, has come back (recurrent), or does not respond to treatment (refractory). ²¹¹At-OKT10-B10 is a monoclonal antibody, called OKT10-B10, linked to a radioactive agent called ²¹¹At. OKT10-B10 attaches to CD38 positive cancer cells in a targeted way and delivers ²¹¹At to kill them. Chemotherapy drugs, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy such as TBI uses high energy x-rays to kill cancer cells and shrink tumors. Giving ²¹¹At-OKT10-B10 together with chemotherapy and TBI before a donor stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells. When the healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets and may help destroy any remaining cancer cells.",[143,27,28],"Multiple Myeloma","2026-06-02",{"date":146,"type":33},"2026-06-04",{"date":148,"type":20},"2027-06-01",{"date":150,"type":20},"2029-12-31",{"name":152,"class":40},"Fred Hutchinson Cancer Center",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":174,"locationsCount":107},"100638264","a-cognitive-training-intervention-for-improving-cognitive-and-neurological-outcomes-in-patients-undergoing-treatment-for-relapsed-or-refractory-multiple-myeloma-or-b-cell-non-hodgkin-lymphoma-100638264","NCT07609030","A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma","Intervention to Enhance Cognitive Augmentation and Neuroplasticity (I-CAN)","Inclusion Criteria:\n\n* Patients \\>= 18 years of age\n* Diagnosed with relapsed\u002Frefractory multiple myeloma (MM) or B-cell non-Hodgkin lymphoma (B-NHL)\n* Expected to receive an Food and Drug administration (FDA)-approved CAR-T cellular treatment\n* English literacy\n\nExclusion Criteria:\n\n* Patients expected to live \\\u003C 6 months\n* Patients with major medical disorder known to affect cognition, such as stroke, encephalitis, traumatic brain injury, brain surgery\n* Confirmed Alzheimer disease or other dementia\n* Previous central nervous system (CNS) radiation\n* Active intrathecal therapy at time of enrollment",{"count":161,"type":20},90,[163],"NA","This clinical trial evaluates whether an online cognitive training intervention (Intervention to enhance Cognitive Augmentation and Neuroplasticity \\[I-CAN\\]), delivered before and after treatment with chimeric antigen receptor T-cell therapy, works to improve cognitive and neurological outcomes in patients with multiple myeloma or B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Cancer treatment can have significant short and long-term side effects, including cognitive and neurological side effects such as impairments in attention, memory, language, and executive function. The I-CAN program is a form of cognitive training. Cognitive training is a therapeutic approach designed to improve and restore cognitive functioning, based on the brain's ability to reorganize and form new neural connections to accomplish tasks. I-CAN provides five core elements necessary for training the brain to create new neural connections including speed of processing, accuracy of processing, adaptivity, generalizability, and engagement. The I-CAN intervention, when delivered before and after therapy, may help reduce the cognitive side effects of treatment in patients with relapsed or refractory multiple myeloma or B-cell non-Hodgkin lymphoma.",[166,27,167,28],"Recurrent B-Cell Non-Hodgkin Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma","2026-05-19",{"date":170,"type":33},"2026-05-27",{"date":172,"type":33},"2026-04-28",{"date":127,"type":20},{"name":175,"class":40},"Ohio State University Comprehensive Cancer Center",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":21,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":4},"100588951","phase-2-testing-the-investigational-medication-combination-of-daratumumab-and-teclistamab-compared-to-the-usual-treatment-daratumumab-pomalidomide-dexamethasone-or-daratumumab-carfilzomib-dexamethasone-for-patients-with-high-risk-multiple-myeloma-refractory-or-in-first-relapse-100588951","NCT06948084","Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)","Inclusion Criteria:\n\n* Patient must be ≥ 18 years of age\n* Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2 (PS 3 allowed if secondary to pain)\n* Patient must have an identifiable dominant sequence (clonotype) established based on Adaptive Biotechnologies clonoSEQ® assay\n* Patient must have received only one prior line of therapy\n\n  * One prior line of systemic therapy is defined as 1 or more cycles of single agent or combination therapy, as well as a series of treatment regimens administered in a sequential manner (e.g., lenalidomide, bortezomib and dexamethasone induction therapy for 4 cycles followed by autologous stem cell transplantation and then lenalidomide +\u002F- proteasome inhibitor or anti-CD38 monoclonal antibody (mAb) maintenance therapy would be considered 1 line of prior therapy)\n  * NOTE: Autologous stem cell transplant is allowed provided the stem cell infusion was \\> 90 days prior to randomization. Allogeneic stem cell transplantation (SCT) patients are ineligible\n* Patient must be diagnosed with relapsed or refractory (RR) multiple myeloma, as defined by disease progression, either an increase in serum or urine M protein of any level, or other evidence of progression biochemical or clinical as specified in the IMWG progression criteria (including disease which becomes non-responsive or progressive on therapy or within 60 days of the last treatment in patients who had achieved a partial response or better on prior therapy)\n* Patient must be daratumumab-hyaluronidase (or isatuximab) naïve or daratumumab-hyaluronidase (or isatuximab) sensitive and \\> 180 days from their last dose of daratumumab-hyaluronidase (or isatuximab) at the time of randomization\n* Patient must have high-risk multiple myeloma (HR-MM) as defined by one of the following either at diagnosis or at refractory status or at first relapse:\n\n  * Evidence of deletion 17p by fluorescence in situ hybridization (FISH) testing on bone marrow\n  * Evidence of t(4;14) by FISH testing on bone marrow\n  * Evidence of t(14;16) by FISH testing on bone marrow\n  * Evidence of t(14;20) by FISH testing on bone marrow\n  * Evidence of chromosome 1 abnormalities either gain\u002Famp 1q or deletion 1p by FISH testing on bone marrow OR\n  * Evidence of non-hyperdiploid karyotype OR\n  * Revised International Staging System (R-ISS) stage III beta2 microglobulin ≥ 5.5 mg\u002FL and serum lactate dehydrogenase (LDH) \\> institutional upper limit of normal (ULN) OR\n  * Patient in first relapse and ≤ 24 months from the start of induction for both allogeneic stem cell transplantation (ASCT) eligible or ASCT ineligible patients (regardless of FISH, cytogenetic or RISS stage)\n* Patient must have measurable disease as defined by having one or more of the following, obtained within 28 days prior to randomization:\n\n  * Serum M protein ≥ 0.5 g\u002FdL (≥ 5 g\u002FL)\n  * Urine M protein ≥ 200 mg\u002F24 hours\n  * Serum free light chain (FLC) assay: Involved free light chain level ≥ 10 mg\u002FdL (≥ 100 mg\u002FL) provided serum FLC ratio is abnormal (\\\u003C 0.26 or \\> 1.65)\n  * Exception: patients without measurable disease in the serum or urine, but with bone or soft tissue plasmacytoma(s) ≥ 2 cm or who have bone marrow plasma cells ≥ 30% are eligible on study\n* Patient must have serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and serum FLC assays along with bone marrow biopsy or aspirate performed within 28 days prior to randomization\n\n  * NOTE: UPEP (on a 24 hour collection) is required, no substitute method is acceptable. Urine must be followed monthly if the baseline urine M-spike is ≥ 200 mg\u002F24 hr. If both serum and urine M-components are measurable, both must be followed in order to confirm response\n  * NOTE: The serum free light chain test is required to be done at each cycle\n* Patient must not have any known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or investigator's brochure), or known sensitivity to mammalian-derived products\n* Patients who have received prior systemic therapy for myeloma, including experimental therapy and steroids must have recovered from clinically significant adverse events prior to randomization\n* Patient may not be on steroids (prednisone \\> 40mg\u002Fday or equivalent) at the time of randomization\n* Patient may have received prior palliative and\u002For localized radiation, provided that it is completed by the time of randomization\n* Absolute neutrophil count (ANC) ≥ 1,000\u002FuL (=\\\u003C 28 days prior to protocol randomization)\n* Untransfused platelet count ≥ 50,000\u002FuL (for patients with ≥ 50% plasma cells in the marrow) and untransfused platelet count \\> 75,000\u002FuL (for patients with \\\u003C 50% plasma cells in the marrow) (=\\\u003C 28 days prior to protocol randomization)\n* Untransfused hemoglobin ≥ 8.0 g\u002FdL (=\\\u003C 28 days prior to protocol randomization)\n* Total bilirubin ≤ 1.5 x institutional ULN (upper limit of normal) (=\\\u003C 28 days prior to protocol randomization)\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 3.0 × institutional ULN (=\\\u003C 28 days prior to protocol randomization)\n* Calculated creatinine clearance \\> 30 mL\u002Fmin (=\\\u003C 28 days prior to protocol randomization)\n\n  * NOTE: Cockcroft-Gault equation should be used to calculate creatinine clearance\n* Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used\n\n  * All patients of childbearing potential must have a blood test or urine study within 14 prior to randomization to rule out pregnancy. Patients randomized to Arm A and to receive the daratumumab-hyaluronidase, pomalidomide, dexamethasone (DPd) regimen must also have a second pregnancy test within 24 hours prior to the first dose of pomalidomide and agree to ongoing pregnancy testing while on protocol treatment\n  * A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\n* Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 5 months after the last dose of protocol treatment for patients on Arm B and for 3 months after the last dose of protocol treatment for patients on Arm A. In addition, patients randomized to Arm A and receive the daratumumab-hyaluronidase, pomalidomide, dexamethasone (DPd) regimen must also agree to register to the mandatory Risk Evaluation and Mitigation Strategies (REMS®) program and be willing and able to comply with the requirements of the REMS program. All patients must not breastfeed while on protocol treatment and for patients on Arm B they must not breastfeed for an additional 5 months after the last dose of protocol treatment\n* Patient may have primary plasma cell leukemia (pPCL), secondary plasma cell leukemia (sPCL) or extramedullary myeloma (EMM)\n* Patient must not have evidence of active or untreated central nervous system (CNS) positive MM. Patients with prior CNS involvement are eligible provided they had demonstrated evidence of CNS disease resolution by imaging and\u002For 2 consecutively negative cerebrospinal fluid (CSF) samples for the presence of plasma cells\n* Patient must not have active autoimmune disease\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better\n* Patients with a history of chronic obstructive pulmonary disease (COPD) must have forced expiratory volume in 1 second (FEV1) testing done within 28 days prior to randomization and the forced expiratory volume in 1 second (FEV1) must be \\>= 50% of predicted normal\n* Patient must not have moderate or severe persistent asthma within 2 years prior to randomization\n\n  * NOTE: Patients who currently have controlled intermittent asthma or controlled mild persistent asthma are eligible\n* Investigator must declare the intended chemotherapy regimen at the time of randomization should their patient be randomized to Arm A from the two options",{"count":184,"type":20},80,[24],"This phase II trial compares the effect of the combination of daratumumab-hyaluronidase (daratumumab) and teclistamab to the usual treatment of daratumumab, pomalidomide, dexamethasone or daratumumab, carfilzomib and dexamethasone in treating patients with multiple myeloma that has not responded to previous treatment (refractory) or that has come back after a period of improvement (relapsed). Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen, a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Pomalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Carfilzomib, a type of proteasome inhibitor, blocks the action of enzymes called proteasomes, which may help keep cancer cells from growing and may kill them. Giving daratumumab and teclistamab may be more effective than the usual treatment of daratumumab, pomalidomide, dexamethasone or daratumumab, carfilzomib and dexamethasone in reducing myeloma cells to undetectable levels in patients with relapsed or refractory multiple myeloma.",[27,28],"2026-05-12",{"date":190,"type":33},"2026-05-13",{"date":192,"type":20},"2026-08-26",{"date":194,"type":20},"2028-02-28",{"name":62,"class":63},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":21,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":107},"100563887","phase-1-sx-682-in-combination-with-carfilzomib-daratumumab-hyaluronidase-and-dexamethasone-in-patients-with-relapsed-or-refractory-multiple-myeloma-100563887","NCT06622005","SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","Phase 1 Trial of SX-682, a CXCR 1\u002F2 Inhibitor, in Combination With Standard of Care Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)","Inclusion Criteria:\n\n* Confirmed relapsed\u002F refractory multiple myeloma\n* Measurable disease including at least one of the following criteria:\n\n  * Serum M-protein ≥ 0.5 g\u002FdL\n  * Urine M-protein ≥ 200 mg\u002F24h\n  * Serum free light chain assay: involved free light chain (FLC) level greater or equal to 100 mg\u002FL provided serum free light chain ratio is abnormal\n  * Bone marrow plasma cells ≥ 10% total bone marrow cells\n* ≥ 1 prior line of therapy\n* Planned treatment with a carfilzomib\u002Fdaratumumab\u002Fdexamethasone regimen\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Absolute neutrophil count: ≥ 3 x 10\\^9\u002FL\n* Platelets: ≥ 75 x 10\\^9\u002FL\n* Hemoglobin: ≥ 7 g\u002FdL\n* Total bilirubin: ≤ 1.5 x upper limit of normal (ULN): ≤ 3.0 x ULN for Gilbert's syndrome\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\]) \u002F alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \\[SGPT\\]): ≤ 3 x ULN\n* Renal Function: Estimated creatinine clearance ≥ 45 mL\u002Fmin (Cockroft-Gault)\n* Left ventricular ejection fraction of at least 50%\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for 6 months following the last dose of the investigational drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Participant must understand the investigational nature of this study and sign an Independent ethics committee\u002Finstitutional review board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Patients with non-secretory myeloma, systemic light chain amyloidosis or, plasmacytoma\n* Intolerance to SX-682 or any other of the treatment components\n* Refractory to prior carfilzomib (i.e. relapse or progression on or within 60 days after completion of treatment)\n* Refractory to prior daratumumab (i.e. relapse or progression on or within 60 days after completion of treatment)\n* Concomitant medication(s) known to be (a) a strong inhibitor or inducer of CYP3A4, or (b) QT prolonging as defined in the drug's approved label, with the exception of drugs that are considered absolutely essential for the care of the subject or if the investigator believes that beginning therapy with such medication is vital to an individual subject's care while on study, and in either case, there is no alternative medication\n* Electrocardiogram (ECG) demonstrating a corrected QT (QTc) interval \\> 470 msec or patients with congenital long QT syndrome\n* Coronary artery bypass, angioplasty, vascular stent, myocardial infarction, angina or congestive heart failure in the last 6 months\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, class III or IV heart failure (New York Heart Association functional classification system) or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* History of hepatitis B, C or HIV\n* Known active bacillus tuberculosis infection\n* Pregnant or nursing female participants\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug",{"count":204,"type":20},15,[23],"This phase I trial tests the safety and side effects of SX-682 in combination with standard of care treatment carfilzomib, daratumumab-hyaluronidase, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). SX-682 works by blocking certain sites on cells that suppress the ability of the immune system to destroy tumor cells. Blocking those specific sites allows other cells of the immune system to become \"free\" to kill tumor cells. Carfilzomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and tumor cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill tumor cells, while hyaluronidase helps to deliver daratumumab to CD38-expressing tumor cells through a subcutaneous injection. Dexamethasone is in a class of medications called corticosteroids. It is known to kill myeloma cells and is also used to reduce inflammation and lower the body's immune response to monoclonal antibodies like dratumumab and help lessen its side effects. Giving SX-682 in combination with carfilzomib, daratumumab-hyaluronidase and dexamethasone may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma",[27,28],"2026-04-16",{"date":210,"type":33},"2026-04-21",{"date":212,"type":33},"2025-04-10",{"date":214,"type":20},"2030-04-10",{"name":216,"class":40},"Roswell Park Cancer Institute",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":21,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":232,"leadSponsor":234,"locationsCount":107},"100606929","phase-1-response-based-dose-reduction-of-linvoseltamab-in-the-treatment-of-relapsed-refractory-or-triple-class-relapsedrefractory-multiple-myeloma-100606929","NCT07181941","Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed\u002FRefractory Multiple Myeloma","Pharmacodynamically Monitored Linvoseltamab Dosing De-Escalation in Relapsed Multiple Myeloma","Inclusion Criteria:\n\n* Age ≥ 18 years. Myeloma is not seen in the younger age group and safety of B-cell maturation antigen (BCMA) T-cell engagers (TCE) in this group is not known\n* Ability to understand and willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of potential study participants\n* Confirmed diagnosis of active multiple myeloma (MM) by International Myeloma Working Group (IMWG) diagnostic criteria\n* Patients must have myeloma that is measurable and response evaluable according to 2016 IMWG response criteria. Measurable disease is defined as one of the following, documented ≤ 14 days prior to registration:\n\n  * Serum M protein ≥ 1 g\u002Fdl\n  * Urine M protein ≥ 200 mg\u002F24h\n  * Free light chain (FLC) assay with involved FLC ≥ 10 mg\u002Fdl and abnormal FLC ratio\n  * A patient with immunoglobulin A (IgA) MM without measurable M protein may be enrolled if quantitative (quant) IgA level ≥ 400 mg\u002Fdl and can be followed longitudinally\n  * Plasmacytoma target lesion defined as measurable based on at least 1 soft tissue lesion ≥ 2 cm in long axis on CT or PET\u002FCT, if not previously irradiated\n  * Skin lesions ≥ 2 cm in long axis as measured with a ruler\n* Patients with relapsed or refractory myeloma who have received at least 4 prior lines of therapy including proteasome inhibitor (PI), immunomodulatory imide drug (IMiD), and anti-CD38 monoclonal antibody\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1\n* Adequate organ function (based on testing ≤14 days prior to registration):\n\n  * Adequate hematologic function before dosing as measured by:\n\n    * Platelet count ≥50 x 10⁹\u002FL. A patient may not have received a platelet transfusion ≤7 days in order to meet this platelet eligibility requirement\n    * Absolute neutrophil count (ANC) ≥1.0 x 10⁹\u002FL. A patient may not have received granulocyte colony stimulating factor (G-CSF) ≤2 days in order to meet this absolute neutrophil count eligibility requirement\n    * Hemoglobin ≥8.0 g\u002FdL\n  * Adequate renal and hepatic function, defined as:\n\n    * Total bilirubin ≤1.5 x ULN\n    * Transaminase (alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\]) ≤2.5 x ULN\n    * Alkaline phosphatase ≤2.5 x ULN\n\n      * Patients with Gilbert syndrome do not need to meet this total bilirubin requirement provided that the total bilirubin is unchanged from the baseline value\n    * Serum creatinine clearance by Cockcroft-Gault ≥30 mL\u002Fmin. A patient with a creatinine clearance by Cockcroft-Gault who does not meet eligibility criteria may be considered for enrollment per principal investigator discretion if a measured creatinine clearance (based on 24-hour urine collection or other reliable method) is ≥30 mL\u002Fmin\n* Prior treatment with BCMA-targeted antibody-drug conjugates (ADCs) is allowable if all adverse events (AEs) attributable to these therapies have resolved to grade 1 or lower\n* Willing and able to comply with clinic visits and study-related procedures and provide informed consent signed by study patient\n\nExclusion Criteria:\n\n* Diagnosis of known plasma cell leukemia, known primary systemic light-chain amyloidosis (excluding myeloma-associated amyloidosis), known Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or known POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)\n* Patients with known MM brain lesions or meningeal involvement\n* History of known neurodegenerative condition, central nervous system (CNS) movement disorder, or patients with a history of seizure within 12 months prior to study enrollment\n* Continuous systemic corticosteroid treatment with more than 10 mg per day of prednisone or anti-inflammatory equivalent within 72 hours of start of study drug\n* Live or live attenuated vaccines with replicating potential within 28 days prior to first study drug administration\n* Previous treatment with chimeric antigen receptor (CAR) T therapy or any gene therapy products\n* Any infection requiring hospitalization or treatment with intravenous (IV) anti-infectives within 2 weeks of first administration of study drug\n* Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV)\n* Known allergy or hypersensitivity to components of linvoseltamab (REGN5458)\n* Women of childbearing potential (WOCBP) with a positive serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test are ineligible for this study\n\n  * WOCBP are defined as women who are fertile following menarche until becoming postmenopausal, unless permanently sterile. Post-menopausal state is defined as no menses for 12 months without an alternate medical cause\n* Participants who are receiving other investigational agents\n* Women of childbearing potential (WCOBP) and men who are unwilling to practice highly effective contraception prior to the initial dose\u002Fstart of the first treatment, during the study, and for at least 6 months after the last dose\n* Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Another malignancy in the past 5 years, except for non-melanoma skin cancer that has undergone potentially curative therapy or in situ cancer, or any other tumor that has been deemed to be effectively treated with definitive local control and with curative intent",{"count":139,"type":20},[23,24],"This phase I\u002FII trial evaluates the safety and feasibility of early, response-based dose reduction of linvoseltamab in the treatment of patients multiple myeloma that has come back after a period of improvement (relapsed), that does not respond to treatment (refractory), or that is resistant to three classes of therapeutic agents, including proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies (triple-class relapsed\u002Frefractory). Linvoseltamab is a bispecific antibody. Upon administration, linvoseltamab binds to the BCMA protein on cancer cells and the CD3 protein on T cells (a type of immune cell). This generates an immune response that stimulates the T cells to kill the cancer cells. Optimal dosing schedules of linvoseltamab have not yet been determined. Reducing the dosage of linvoseltamab may reduce treatment-related side effects while maintaining long-term disease outcomes.",[27,28],"2026-03-24",{"date":230,"type":33},"2026-03-27",{"date":228,"type":33},{"date":233,"type":20},"2028-06-30",{"name":152,"class":40},{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":21,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":107},"100588353","phase-2-dasatinib-and-quercetin-with-car-t-therapy-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma-100588353","NCT06940297","Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","DART: Phase II Study of Dasatinib and Quercetin in Patients With Relapsed, Refractory Multiple Myeloma Receiving CAR-T Therapy","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Relapsed or refractory multiple myeloma who has had at least 3 prior lines of therapies including a proteasome inhibitor, immunomodulatory drug (IMiD) and anti-CD38 monoclonal antibody (mAb)\n* Ciltacabtagene autoleucel (Carvykti) available for patient\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2\n* Life expectancy ≥ 12 weeks\n* Hemoglobin ≥ 8.0 g\u002FdL (obtained ≤ 14 days prior to registration)\n* Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm\\^3 (obtained ≤ 14 days prior to registration)\n* Platelet count ≥ 50,000\u002Fmm\\^3 (obtained ≤ 14 days prior to registration)\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to registration)\n\n  * Note: Patients with Gilbert's syndrome must have a total bilirubin of ≤ 3 x ULN (obtained ≤ 14 days prior to registration)\n* Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2 x ULN (obtained ≤ 14 days prior to registration)\n* Alkaline phosphatase ≤ 1.5 x ULN (obtained ≤ 14 days prior to registration)\n* Calculated creatinine clearance ≥ 30 ml\u002Fmin using the Cockcroft-Gault formula (obtained ≤ 14 days prior to registration)\n* Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only\n\n  * Note: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate prior to study entry and for the duration of study participation and for at least 30 days after the last dose of study drug\n* Provide written informed consent\n* Willingness to provide mandatory blood and bone marrow specimens for correlative research\n* Willingness to provide mandatory bone marrow cores and\u002For tissue specimens for correlative research\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or AL amyloidosis\n* Failure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment.\n\n  * EXCEPTION: Grade 1 peripheral (sensory) neuropathy that has been stable for at least 1 month since completion of prior treatment\n* Any of the following because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects:\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential (and persons able to father a child) who are unwilling to employ adequate contraception\n* Major surgery ≤ 28 days prior to registration\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Immunocompromised patients and patients known to be HIV positive.\n\n  * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, or those currently receiving antiretroviral therapy with good control of HIV, are eligible for this trial\n* Evidence of cardiovascular disease risk, as defined by any of the following:\n\n  * Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block\n  * History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within three (3) months of screening.\n  * Class III or IV heart failure as defined by the New York Heart Association functional classification system\n  * Uncontrolled hypertension\n  * History of life-threatening ventricular arrhythmias\n  * QTC interval \\[electrocardiogram (ECG)\\] ≥ 450 msec\n* Uncontrolled intercurrent illness including, but not limited to:\n\n  * Ongoing or active infection\n  * Any medical condition that would make participation unduly hazardous\n* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm\n* Live vaccine ≤ 6 weeks prior to registration\n* Has taken a strong inhibitor or inducer of CYP3A4\u002F5, including grapefruit, St. John's Wort or related products ≤ 14 days prior to registration.\n\n  * Note: If required, patients may receive a short course of strong inhibitors or inducers for treatment of symptoms, but dasatinib dose must be adjusted as indicated\n* Known hypersensitivity or allergy to dasatinib or quercetin\n* Patients on therapeutic doses of anticoagulants (e.g. warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc).\n* On antiplatelet agents (e.g. full dose aspirin, clopidogrel etc.)\n\n  * NOTE: Baby aspirin, if necessary for cardioprotection, will be allowed\n* On quinolone antibiotic therapy for treatment or for prevention of infections products ≤10 days prior to registration",{"count":243,"type":20},44,[24],"This phase II trial tests how well giving dasatinib and quercetin with cyclophosphamide, fludarabine and chimeric antigen receptor (CAR)-T cell therapy works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Quercetin is a compound found in plants that may prevent multiple myeloma from forming. Chemotherapy such as cyclophosphamide and fludarabine are given to help kill any remaining cancer cells in the body and to prepare the bone marrow for CAR-T therapy. Chimeric antigen receptor T-cell Therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving dasatinib and quercetin with cyclophosphamide, fludarabine and CAR-T cell therapy may kill more cancer cells in patients with relapsed or refractory multiple myeloma.",[27,28],"2026-02-04",{"date":249,"type":33},"2026-02-06",{"date":251,"type":33},"2025-06-23",{"date":253,"type":20},"2031-08-15",{"name":106,"class":40},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":21,"phases":264,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":107},"100504381","phase-2-alternate-doses-and-dosing-schedules-of-belantamab-mafodotin-for-treatment-of-triple-class-refractory-multiple-myeloma-100504381","NCT05847569","Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma","Phase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Class Refractory Multiple Myeloma","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2\n* Histologically or cytologically confirmed diagnosis of multiple myeloma (MM), as defined in International Myeloma Working Group (IMWG) criteria, and:\n\n  * If patients have undergone stem cell transplantation (SCT), day 0 of SCT must be \\> 100 days prior to registration to be eligible for the study\n  * Has had disease progression after \\>= 3 prior lines of anti-myeloma treatments including one proteasome inhibitor (eg. bortezomib, carfilzomib or ixazomib), one immunomodulatory agent (eg.thalidomide, lenalidomide or pomalidomide) and one anti-CD38 monoclonal antibody (eg.daratumumab or isatuximab)\n  * Prior non-belantamab mafodotin anti-BCMA agent exposure is allowed; patients with prior treatment with an anti-BCMA chimeric antigen receptor (CAR)-T or bispecific antibody will be allowed to participate in the study\n* Has measurable disease with at least one of the following:\n\n  * Serum M-protein \\>= 0.5 g\u002FdL (\\>= 5 g\u002FL)\n  * Urine M-protein \\>= 200 mg\u002F24 h\n  * Serum free light chain (FLC) assay: Involved FLC level \\>= 10 mg\u002FdL (\\>= 100 mg\u002FL) and an abnormal serum free light chain ratio (\\\u003C 0.26 or \\> 1.65)\n  * Note: Patients with non-secretory disease will be allowed to participate\n* Absolute neutrophil count \\>= 0.75 x 10\\^9\u002FL (=\\\u003C 28 days prior to registration)\n\n  * Without growth factor support, blood transfusion, or platelet stimulating agents for the past 14 days, excluding erythropoietin\n* Hemoglobin \\>= 7.0 g\u002FdL (=\\\u003C 28 days prior to registration)\n\n  * Without growth factor support, blood transfusion, or platelet stimulating agents for the past 14 days, excluding erythropoietin\n* Platelets \\>= 50 x 10\\^9\u002FL (=\\\u003C 28 days prior to registration)\n\n  * Without growth factor support, blood transfusion, or platelet stimulating agents for the past 14 days, excluding erythropoietin\n* Total bilirubin =\\\u003C 2.0 x upper limit of normal (ULN) (=\\\u003C 28 days prior to registration); (total bilirubin \\>= 2.0 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is \\\u003C 35%)\n* Alanine aminotransferase =\\\u003C 2.5 x ULN (=\\\u003C 28 days prior to registration)\n* Aspartate transaminase =\\\u003C 2.5 x ULN (=\\\u003C 28 days prior to registration)\n* Estimated glomerular filtration rate (eGFR) \\>= 30 mL\u002Fmin\u002F1.73 m\\^2 (=\\\u003C 28 days prior to registration)\n\n  * As calculated by Modification of Diet in Renal Disease (MDRD) formula\n* Spot urine \\[albumin\u002Fcreatinine ratios (spot urine)\\] =\\\u003C 500 mg\u002Fg (56 mg\u002Fmmol) OR urine dipstick negative\u002Ftrace \\[if \\>1+ only eligible if confirmed =\\\u003C 500 mg\u002Fg (56 mg\u002Fmmol) by albumin\u002Fcreatinine ratio (spot urine from first void)\\] (=\\\u003C 28 days prior to registration)\n* Negative pregnancy test done =\\\u003C 7 days prior to registration, for persons of childbearing potential only. Both females and males must agree to follow the instructions\n\n  * NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Provide written informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol\n* Willingness to provide mandatory blood specimens for correlative research\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Active plasma cell leukemia at the time of screening. Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, myeloma protein, and skin changes), Waldenstrom Macroglobulinemia\n* Prior belantamab mafodotin therapy. However, patients with prior exposure to another non-belantamab mafodotin anti-BCMA agent such as an anti-BCMA CAR-T or anti-BCMA bispecific antibody will be allowed to participate in the study\n* Systemic active infection requiring treatment\n* Any unresolved toxicity \\>= grade 2 from previous treatment except for alopecia, or peripheral neuropathy up to grade 2\n* Any major surgery =\\\u003C 4 weeks prior to registration\n* Any serious and\u002For unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities except renal impairment) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures\n* Evidence of active mucosal or internal bleeding\n* Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if participant otherwise meets entry criteria\n* Participants with previous or concurrent malignancies other than multiple myeloma are excluded, unless the prior malignancy has been considered medically stable for \\> 2 years. The participant must not be receiving active therapy, other than hormonal therapy for this disease. NOTE: Participants with curatively treated nonmelanoma skin cancer are allowed without a 2-year restriction.\n* Evidence of cardiovascular risk, including any of the following:\n\n  * Evidence of current clinically significant untreated arrhythmias, including clinically significant electrocardiogram (ECG) abnormalities including 2nd degree (Mobitz type II) or 3rd degree atrioventricular (AV) block\n  * History of myocardial infarction (=\\\u003C 6 months), acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 12 weeks of screening\n  * Class III or IV heart failure as defined by the New York Heart Association functional classification system \\[NYHA, 1994\\]\n  * Uncontrolled hypertension\n* Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, or any of the components of the study treatment\n* Known human immunodeficiency virus (HIV) infection, unless the participant can meet all of the following criteria:\n\n  * Established anti-retroviral therapy (ART) for at \\>=4 weeks and HIV viral load \\\u003C 400 copies\u002FmL\n  * CD4+ T-cell (CD4+) counts \\>= 350 cells\u002FuL\n  * No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections \\\u003C 12 months prior\n  * Note: consideration must be given to ART and prophylactic antimicrobials that may have a drug-drug interaction and\u002For overlapping toxicities with belantamab mafodotin or other combination products as relevant\n* Patients with hepatitis B will be excluded unless the following criteria can be met:\n\n  * If patient's serology shows hepatitis B virus core antibody (HbcAb)+ and hepatitis B surface antigen (HbsAg)-, they must have undetectable hepatitis B virus (HBV) deoxyribonucleic acid (DNA) at screening. Patients will be monitored per protocol. Antiviral treatment would be instituted if HBV DNA becomes detectable\n  * If patient's serology shows HBsAg+ at screen or within 3 months prior, patients must have undetectable HBV DNA at screening, must have started highly effective antiviral treatment at least 4 weeks prior to registration, and must have baseline imaging per protocol (patients with cirrhosis are excluded). Patients must remain on antiviral treatment throughout the study. Patients will be monitored per protocol\n  * Note: presence of hepatitis (Hep) B surface antibody (HBsAb) indicating previous vaccination will not exclude a participant.\n* Positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or =\\\u003C 12 weeks prior to first dose of study treatment unless the participant can meet the following criteria:\n\n  * RNA test negative\n  * Successful anti-viral treatment (usually 8 weeks duration) is required, followed by a negative HCV RNA test after a washout period \\>= 4 weeks\n* Current corneal epithelial disease except for mild punctuate keratopathy\n* Participant who received plasmapheresis within =\\\u003C 7 days prior to registration\n* Patients who received prior allogeneic stem cell transplant\n* Participant who received a live or live-attenuated vaccine =\\\u003C 30 days prior to registration. Ok to receive coronavirus disease (COVID) vaccine at any timepoint during protocol treatment\n* Participant is a woman who is pregnant or lactating\n* Participant who plans on wearing contact lenses during treatment with belantamab mafodotin\n\nLifestyle Considerations:\n\nContact lenses are prohibited for participants while they are receiving belantamab mafodotin treatment. Contact lens use may be restarted after belantamab mafodotin treatment is discontinued, provided a qualified eye care specialist confirm there are no other contraindications. Use of bandage contact lenses is allowed for the treatment of corneal epithelial disease as prescribed by an ophthalmologist\u002Feye care professional.\n\nNo other lifestyle restrictions are required for participants in this study.",{"count":263,"type":20},62,[24],"This phase II trial tests alternate doses and dosing schedules of belantamab mafodotin in treating patients with triple-class multiple myeloma that has come back (after a period of improvement) (recurrent) and\u002For does not respond to treatment (or that has not responded to previous treatment) (refractory). Belantamab mafodotin is a monoclonal antibody, belantamab, linked to a chemotherapy drug, mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as BCMA receptors, and delivers mafodotin to kill them. This trial may help researchers determine if alternate doses and dosing schedules work better in preventing certain side effects, such as eye toxicity, and treating patients with recurrent or refractory multiple myeloma.",[27,28],"2026-01-30",{"date":269,"type":33},"2026-02-03",{"date":271,"type":33},"2024-01-04",{"date":273,"type":20},"2034-06-29",{"name":106,"class":40},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":21,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":107},"100564328","phase-2-mezigdomide-carfilzomib-and-dexamethasone-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma-in-patients-with-extramedullary-disease-100564328","NCT06627751","Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease","Phase II Clinical Trial of Mezigdomide\u002FCarfilzomib\u002FDexamethasone (MeziKD) in Patients With Relapsed or Refractory Multiple Myeloma (MM) With Extramedullary Disease (EMD)","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2\n* RRMM patients with one or more prior lines of therapy with at least one ES or PS lesion that is accessible to a biopsy. Accessibility will be assessed by the MM tumor board\n* Measurable disease meeting at least one of the following:\n\n  * Serum M-protein ≥1 g\u002FdL\n  * Urine M-protein ≥200 mg\u002F24 h\n  * Serum FLC assay: involved FLC level ≥10 mg\u002FdL provided serum FLC ratio is abnormal\n  * Up to 10 patients without measurable disease can be enrolled but screening imaging and\u002For bone marrow biopsy have to confirm RRMM. Follow-up response assessment will be performed with imaging using RECIST 1.1 and Deauville Criteria and bone marrow biopsies\n* Absolute neutrophil count: ≥ 1 x 10\\^9\u002FL\n* Platelets: ≥ 75 x 10\\^9\u002FL\n* Total bilirubin: ≤ 1.5 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]): ≤ 3 x ULN\n* Renal function: Estimated creatinine clearance ≥ 30 mL\u002Fmin (Cockroft-Gault)\n* Adequate cardiac pump function with a left ventricular ejection fraction of ≥ 40%\n* Women of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for at least 28 days after the last dose of mezigdomide or 6 months after the last dose of carfilzomib. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Male patients (non-vasectomized) must agree to use contraception during the treatment period and for at least 28 days after the last dose of mezigdomide or 3 months after the last dose of carfilzomib and refrain from donating sperm during this period\n* Participant must understand the investigational nature of this study and sign an independent ethics committee\u002Finstitutional review board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Participant has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, pomalidomide (including ≥ grade 3 rash during prior thalidomide, lenalidomide, or pomalidomide therapy), carfilzomib or dexamethasone, any cereblon E3 ligase modulators (CELMoD) agents, or the excipients contained in the formulations, or participant has any contraindications per local prescribing information\n* Administration of strong CYP3A modulators or proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole) within 2 weeks of starting study intervention\n* Participant is unable or unwilling to undergo protocol required thromboembolism prophylaxis\n* Patient has evidence of mucosal or internal bleeding and\u002For is platelet transfusion refractory\n* Any medical conditions that, in the investigator's opinion, would impose excessive risk to the patient or would adversely affect his\u002Fher participation in this study\n* Known active infection requiring parenteral or oral anti-infective treatment within the past 14 days\n* Participant has a history of prior malignancy other than MM, except if the participant has been free of disease for ≥ 3 years or the participant had 1 of the following noninvasive malignancies treated with curative intent without known recurrence:\n\n  * Basal or squamous cell carcinoma of the skin\n  * Carcinoma in situ of the cervix or breast\n  * Stage 1 bladder cancer\n  * Incidental histological findings of localized prostate cancer such as tumor stage 1a or 1b (T1a or T1b) using the tumor, nodes, and metastasis (TNM) classification of malignant tumors OR prostate cancer that has been treated with curative intent\n* Other ongoing anti-myeloma therapy. Patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids for symptom management and comorbid conditions. Doses of corticosteroid should be stable for at least 7 days prior to patient registration\n* Pregnant or breast-feeding females\n* Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse follow-up evaluation\n* Known active HIV or hepatitis B or C viral infection\n* Known history of HIV infection\n* Systemic amyloidosis or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein \\[M-protein\\] and skin changes)\n* Prior peripheral stem cell transplant within 12 weeks of study enrollment\n* Radiotherapy within 14 days prior to cycle 1 day 1. However, if the radiation portal covered ≤ 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy\n* Known intolerance to steroid therapy\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, severe cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Carfilzomib-refractory in the most recent line of therapy\n* Prior treatment with mezigdomide\n* Contraindication against conscious sedation\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug",{"count":283,"type":20},28,[24],"This phase II trial studies how well mezigdomide\u002Fcarfilzomib\u002Fdexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and have tumors from myeloma cells outside the bone marrow in the soft tissues or organs of the body (extramedullary disease \\[EMD\\]). Mezigdomide blocks important processes in myeloma cells and may lead to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a type of corticosteroid and is used to kill myeloma cells. It is used with other drugs to treat multiple myeloma. Giving MeziKD may kill more cancer cells in patients with relapsed\u002Frefractory multiple myeloma (RRMM) with EMD.",[287,27,28],"Extramedullary Disease in Multiple Myeloma","2026-01-09",{"date":290,"type":33},"2026-01-12",{"date":292,"type":33},"2025-05-01",{"date":294,"type":20},"2030-05-01",{"name":216,"class":40}]